Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT ID: NCT01665794
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
25 participants
INTERVENTIONAL
2012-08-13
2025-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PdC Group
Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
Pomalidomide
Pomalidomide taken orally at assigned dose.
Carfilzomib
Carfilzomib given by intravenous (IV) infusion at assigned dose.
dexamethasone
Dexamethasone taken orally of given by IV infusion.
PdC + Dara Group
Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
Pomalidomide
Pomalidomide taken orally at assigned dose.
Carfilzomib
Carfilzomib given by intravenous (IV) infusion at assigned dose.
dexamethasone
Dexamethasone taken orally of given by IV infusion.
Daratumumab
Daratumumab given by intravenous (IV) infusion at assigned dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pomalidomide
Pomalidomide taken orally at assigned dose.
Carfilzomib
Carfilzomib given by intravenous (IV) infusion at assigned dose.
dexamethasone
Dexamethasone taken orally of given by IV infusion.
Daratumumab
Daratumumab given by intravenous (IV) infusion at assigned dose.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failed at least one prior treatment for multiple myeloma (must have received lenalidomide)
* To be enrolled as second line therapy: Must be refractory to lenalidomide (progression on therapy or within 60 days of lenalidomide dosing)
* Measurable disease, as indicated by one or more of the following:
* Serum M-protein \>= 0.5 g/dL
* Urine M-protein \>= 200 mg/24 hours
* If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable
* Involved serum free light chains ≥ 10 mg/dL (free light change ratio must be abnormal)
* Aged 18 years or older
* Life expectancy of more than 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Adequate Liver Function
* Bilirubin \< 1.5 times the upper limit of normal (ULN)
* Aspartate aminotransferase (AST) \< 2.5 times ULN
* Alanine aminotransferase (ALT) \< 2.5 times ULN
* Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L
* Hemoglobin \>= 8 g/dL
* Platelet count \>= 75 x 10\^9/L (should be independent of platelet transfusions for at least 2 weeks)
* Calculated or measured creatinine clearance of \>= 30 mL/minute
* Written informed consent
* Negative pregnancy test (for women of childbearing potential) within 10-14 days of starting study treatment and again within 24 hours of first pomalidomide dose
* Must agree to practice abstinence or use two acceptable methods of birth control
* Men must agree to use latex condom during sexual contact with women of childbearing potential (even if post vasectomy)
* Must agree to adhere to all study requirements, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoring
* Must register to mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program
Exclusion Criteria
* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
* Plasma cell leukemia
* Waldenström's macroglobulinemia or immunoglobulin M (IgM) myeloma
* Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)
* Participation in an investigational therapeutic study within 3 weeks or within 5 drug half lives (t1/2) prior to first dose, whichever time is greater
* Patients known to be refractory to any proteasome inhibitor other than bortezomib or carfilzomib
* Pregnant or lactating
* History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide
* Major surgery within 3 weeks prior to first dose,
* Prior peripheral stem cell transplant within 12 weeks of study enrollment
* Has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for thyroid conditions or estrogen replacement therapy \[ERT\]), or any investigational therapy within 21 days of enrollment
* Myocardial infarction within 6 months prior to enrollment, New York Heart Associate (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
* Uncontrolled hypertension or diabetes
* Acute active infection requiring systemic antibiotics, antivirals, or anti fungals within two weeks prior to first dose
* Known or suspected human immunodeficiency (HIV) infection, known HIV seropositivity
* Active hepatitis A, B, or C infection
* Non-hematologic malignancy within the past 3 years except adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix or breast, prostate cancer \< Gleason grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone
* Any clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
* Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
* Contraindications to any of the required concomitant drugs, including proton-pump inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
* Subjects in whom the required program of PO and IV fluid hydration is contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment
* Subjects with known or suspected amyloidosis of any organ
* Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
* Prior exposure to daratumumab
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Multiple Myeloma Research Foundation
OTHER
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrzej Jakubowiak
Role: PRINCIPAL_INVESTIGATOR
University of Chicago Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Wayne State University - Karmonos Cancer Center
Detroit, Michigan, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University Health Network - Princess Margaret Cancer Center
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, Major A, Kin A, Griffith K, Jasielec J, Jakubowiak AJ. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 Oct 10;7(19):5703-5712. doi: 10.1182/bloodadvances.2022008866.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-01168
Identifier Type: REGISTRY
Identifier Source: secondary_id
12-1088
Identifier Type: -
Identifier Source: org_study_id